spacer
home > ebr > winter 2018 > situation critical
PUBLICATIONS
European Biopharmaceutical Review

Situation Critical

In February 2017, the Boston Consulting Group published Breaking Through the Wall – a report calling for concerted action on antibiotics R&D and the creation of a global union for antibiotics R&D. One of its most shocking statistics was the number of scientists on the ground working globally in antibiotics research – less than 500 in the industry worldwide. Since the report came out, further job reductions have been announced, and fewer than 100 antimicrobial resistance (AMR) researchers are now estimated to remain in the UK industry. This figure is particularly alarming in comparison with the number of scientists working in other fields. For example, Cancer Research UK is reported to fund more than 4,000 research scientists in the UK alone.

The low number of researchers is one of a long list of worrying figures in AMR. Cases of antibiotic-resistant infections have been rising steeply over the past 15 years, with almost 60% of Escherichia coli infections now resistant to penicillins. Lord O’Neill’s AMR review predicted that, by 2050, AMR will account for over 10 million deaths per year worldwide, more than those attributable to cancer. By the same year, if no new antibiotics are developed, the impact on the global economy will be $100 trillion.

Warning signs are already present that the future pipeline of new treatments is in danger. According to intellectual property lawyers Marks and Clerk, antibiotic patent applications worldwide dropped by over a half from 2004 to 2013. Additionally, fewer new drugs are emerging from clinical trials, with only two new molecular entities being approved by US regulators between 2008 and 2012, down from 16 in the early 1980s. Most worryingly of all, no new classes of antibiotics that are effective against the most serious gram-negative infections have been introduced in 55 years.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 10 years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Peter has over 25 years’ experience in the sector, previously holding senior executive roles as Commercial Director then Vice President of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI. During 2015-16, Peter was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.
spacer
Dr Peter Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Expands Services for Early Discovery Screening

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.
More info >>

White Papers

Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments

World Courier

It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>

 
Industry Events

T3: Trials, Tech and Transformation

30-31 May 2018, Raleigh Convention Center, Raleigh, NC

T3 is back for 2018 to provide you with the latest updates and top tips from across the clinical trials landscape. Connecting leading experts, influencers and innovators from pharma, biotech, CROs, patient advocacy groups, academia and beyond, T3 is themeeting place for all stakeholders to voice their questions, connect with peers, and get direct feedback from an expert speaker line-up.And this year, we're in Raleigh.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement